Aprea to Unveil Early APR-1051 Safety, Efficacy Data at ASCO May 30
Aprea Therapeutics will present early Phase 1 data for its oral WEE1 inhibitor APR-1051 in advanced solid tumors at ASCO 2026 on May 30. The poster (Board 244) reports first-in-human safety and initial efficacy findings from the ACESOT-1051 trial (NCT06260514).
1. ASCO Presentation Scheduled
Aprea’s abstract “Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)” has been accepted for a poster at the ASCO 2026 Annual Meeting on May 30, 1:30–4:30 PM CDT at Poster Board 244. Shiraj Sen, MD, PhD, will discuss initial safety and efficacy observations.
2. ACESOT-1051 Trial Design
The first-in-human, dose-escalation Phase 1 study (NCT06260514) evaluates oral APR-1051 in adult patients with biomarker-defined advanced solid tumors. Primary endpoints include safety, tolerability and recommended Phase 2 dose, with secondary measures of preliminary anti-tumor activity.
3. Pipeline and Next Steps
APR-1051 represents Aprea’s lead WEE1 inhibitor program and this early data readout could de-risk downstream trials and support potential collaborations. Results may influence Phase 2 planning and broader development across ovarian, colorectal and head and neck cancer indications alongside ATRN-119.